Macquarie Group
ATXS

Macquarie Group’s Astria Therapeutics ATXS Stock Holding History

Macquarie Group’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,658
Closed -$42 – 1714
2024
Q4 		$42 Buy
+4,658
New +$49.5K ﹤0.01% 1646
2024
Q3 		– Sell
-219
Closed -$1.99K – 1672
2024
Q2 		$1.99K Buy
+219
New +$2.14K ﹤0.01% 1802
2019
Q1 		– Sell
-210
Closed -$6K – 1666
2018
Q4 		$6K Buy
+210
New +$7.95K ﹤0.01% 2039
2018
Q1 		– Sell
-87
Closed -$8K – 2177
2017
Q4 		$8K Buy
+87
New +$10.2K ﹤0.01% 2300

Other funds holding ATXS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Macquarie Group's ATXS Position: Q1 2025 in Review

Macquarie Group sold out of Astria Therapeutics (ATXS) in Q1 2025, closing a stake of 4,658 shares — an estimated $42 sold.

Macquarie Group first reported a position in ATXS in Q4 2017 and held it in 4 quarters. The position peaked at $8K in Q4 2017. 115 funds tracked by Wall St. Rank hold ATXS as of Q1 2025.

  • Macquarie Group reported no remaining Astria Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Macquarie Group sold 4,658 Astria Therapeutics shares in Q1 2025, an estimated $42.
  • Macquarie Group first reported a position in Astria Therapeutics in Q4 2017 and held it in 4 quarters.
  • Macquarie Group's Astria Therapeutics position peaked at $8K in Q4 2017.
  • 115 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2025.

Based on Macquarie Group's 13F filing for Q1 2025, filed 15 May 2025.